Markets:

Overview

News

Currencies

International

Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

20.84 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

53 54 Next >

Surging Oil Prices Spark Market Jitters ↗

March 25, 2026

The Motley Fool's Hidden Gems team discusses some historical disruptions in the energy market, how trends in semiconductors are reshaping the S&P 500, and why Hims & Hers stock is soaring.

Via The Motley Fool

HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm

March 25, 2026

From Schall Law

Via GlobeNewswire

2 Healthcare Stocks to Target This Week and 1 That Underwhelm

March 23, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

This Hims & Hers Move Could Destroy Competitors ↗

March 21, 2026

The Wegovy pill could change Hims & Hers' growth in 2026.

Via The Motley Fool

Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? ↗

March 20, 2026

The healthcare stock has lost more than half of its value in the past year.

Via The Motley Fool

1 Growth Stock with All-Star Potential and 2 That Underwhelm

March 19, 2026

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Via StockStory

Hims & Hers Opens Waitlist For $149 Branded Wegovy And Ozempic Via Novo Nordisk Deal ↗

March 18, 2026

Hims & Hers Health, Inc. (NYSE:HIMS) trended on Wednesday after the company outlined an expanded weight-management push tied to

Via Benzinga

Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot

March 18, 2026

As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year...

Via Finterra

Topics Intellectual Property

Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk ↗

March 18, 2026

The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform.

Via Stocktwits

Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move ↗

March 17, 2026

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Via The Motley Fool

Topics Stocks

Hims & Hers Health Stock Slips After Surging 50% In A Month ↗

March 16, 2026

Hims & Hers Health Inc (NYSE: HIMS) shares are pulling back Monday morning, giving back a portion of last week's sharp rally.

Via Benzinga

Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗

March 16, 2026

The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Via The Motley Fool

MarketBeat Week in Review – 03/09 - 03/13 ↗

March 14, 2026

Despite continued volatility, stocks have stayed resilient as investors navigate the fog of war. The story is largely about oil. When the price of crude oil goes up, stocks go down and vice versa....

Via MarketBeat

The Great Pivot: How the Novo Nordisk Deal Transformed Hims & Hers (HIMS) into a Healthcare Powerhouse

March 13, 2026

As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from...

Via Finterra

Topics Economy

Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking ↗

March 12, 2026

On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth growth.

Via The Motley Fool

Topics Intellectual Property Stocks

Does This Deal Make Novo Nordisk Stock a Buy? ↗

March 12, 2026

Not many things have gone right for Novo Nordisk recently, but this is one of them.

Via The Motley Fool

Topics Intellectual Property Lawsuit

The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot

March 12, 2026

As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers...

Via Finterra

Why Hims & Hers Health (HIMS) Stock Is Surging In Thursday's Premarket ↗

March 12, 2026

HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims & Hers Health Inc (NYSE: HIMS) higher.

Via Benzinga

1 Value Stock with Exciting Potential and 2 We Ignore

March 12, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

These stocks are making the most noise in today's session. ↗

March 11, 2026

Via Chartmill

Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War

March 11, 2026

The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant...

Via MarketMinute

Topics Economy Intellectual Property Lawsuit

HIMS Stock Jumps 14% – Barclays Says Market Is Underestimating Opportunity From New Products ↗

March 11, 2026

Brokerages have turned bullish on HIMS since its deal with Novo Nordisk earlier this week, with Barclays raising the stock’s price target to $29.

Via Stocktwits

Topics Intellectual Property Lawsuit

Short Seller Who Bet Against Hims & Hers Now Says Its CEO 'Wiped The Floor' With Novo Nordisk ↗

March 11, 2026

Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.

Via Stocktwits

Topics Bankruptcy Fraud Intellectual Property

3 Big Reasons to Love Hims & Hers Health (HIMS)

March 11, 2026

Hims & Hers Health has gotten torched over the last six months - since September 2025, its stock price has dropped 55.2% to $23.21 per share. This may have i...

Via StockStory

Hims & Hers Names Kathryn Beiser as Chief Communications Officer

March 10, 2026

From Hims & Hers

Via Business Wire

Asset Manager Exits Shares of Hims & Hers Health ↗

March 10, 2026

Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.

Via The Motley Fool

Topics Regulatory Compliance

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal ↗

March 10, 2026

Via MarketBeat

Disrupting the Pharmacy: A Deep-Dive into Hims & Hers Health (HIMS) in 2026

March 10, 2026

As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a...

Via Finterra

Topics Artificial Intelligence Economy

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗

March 10, 2026

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

Via Stocktwits

Topics Intellectual Property Lawsuit

Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers

March 10, 2026

From Hims & Hers

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.